NextCure (NXTC) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $6.24, -9.30% vs the prior close of $6.88.
- Volume 39.00K shares, 0.3x its 50-day average (light).
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
NXTC slides 9.3% to $6.24. Closed at $6.24, -9.30% vs the prior close of $6.88. Day range $6.10–$6.66, opened at $6.61.
NXTC daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — NXTC slides 9.3% to $6.24
- Closed at $6.24, -9.30% vs the prior close of $6.88. Day range $6.10–$6.66, opened at $6.61.
- Volume was 39.00K shares, 0.3x its 50-day average of 150.35K — lighter than usual.
- Price is -2.5% vs its 50-day average ($6.40) and -24.3% vs its 200-day average ($8.24).
- 52-week range $1.55–$15.74; today's close sits at 33% of that range, 60.4% below the 52-week high.
Oct 15, 2026 — NXTC jumps 4.6% to $6.88
- Closed at $6.88, +4.56% vs the prior close of $6.58. Day range $6.59–$7.22, opened at $6.59.
- Volume was 72.40K shares, 0.5x its 50-day average of 153.51K — lighter than usual.
- Price is +7.7% vs its 50-day average ($6.39) and -16.9% vs its 200-day average ($8.28).
- 52-week range $1.55–$15.74; today's close sits at 38% of that range, 56.3% below the 52-week high.
Oct 14, 2026 — NXTC jumps 4.8% to $6.58
- Closed at $6.58, +4.78% vs the prior close of $6.28. Day range $6.11–$6.86, opened at $6.16.
- Volume was 51.60K shares, 0.3x its 50-day average of 163.20K — lighter than usual.
- Price is +3.5% vs its 50-day average ($6.35) and -20.8% vs its 200-day average ($8.31).
- 52-week range $1.55–$15.74; today's close sits at 35% of that range, 58.2% below the 52-week high.
Oct 13, 2026 — NXTC slides 5.4% to $6.28
- Closed at $6.28, -5.42% vs the prior close of $6.64. Day range $6.21–$6.80, opened at $6.58.
- Volume was 54.70K shares, 0.3x its 50-day average of 171.04K — lighter than usual.
- Price is -0.9% vs its 50-day average ($6.34) and -24.7% vs its 200-day average ($8.34).
- 52-week range $1.55–$15.74; today's close sits at 33% of that range, 60.1% below the 52-week high.
Oct 12, 2026 — NXTC slides 7.5% to $6.64
- Closed at $6.64, -7.52% vs the prior close of $7.18. Day range $6.03–$7.52, opened at $7.08.
- Volume was 130.40K shares, 0.7x its 50-day average of 176.14K.
- Price is +5.4% vs its 50-day average ($6.30) and -20.7% vs its 200-day average ($8.37).
- 52-week range $1.55–$15.74; today's close sits at 36% of that range, 57.8% below the 52-week high.
Oct 9, 2026 — NXTC jumps 5.9% to $7.18, 4 up days in a row
- Closed at $7.18, +5.90% vs the prior close of $6.78. Day range $6.30–$7.20, opened at $6.68.
- Volume was 85.70K shares, 0.4x its 50-day average of 192.09K — lighter than usual.
- Price is +14.9% vs its 50-day average ($6.25) and -14.6% vs its 200-day average ($8.40).
- 52-week range $1.55–$15.74; today's close sits at 40% of that range, 54.4% below the 52-week high.
- That makes 4 straight gains.
Oct 8, 2026 — NXTC jumps 3.4% to $6.78, 3 up days in a row
- Closed at $6.78, +3.35% vs the prior close of $6.56. Day range $6.05–$6.94, opened at $6.24.
- Volume was 82.60K shares, 0.4x its 50-day average of 197.55K — lighter than usual.
- Price is +9.2% vs its 50-day average ($6.21) and -19.5% vs its 200-day average ($8.42).
- 52-week range $1.55–$15.74; today's close sits at 37% of that range, 56.9% below the 52-week high.
- That makes 3 straight gains.
Oct 7, 2026 — NXTC jumps 15.4% to $6.56
- Closed at $6.56, +15.39% vs the prior close of $5.68. Day range $5.42–$6.72, opened at $5.70.
- Volume was 109.50K shares, 0.5x its 50-day average of 200.09K — lighter than usual.
- Price is +6.3% vs its 50-day average ($6.17) and -22.3% vs its 200-day average ($8.45).
- 52-week range $1.55–$15.74; today's close sits at 35% of that range, 58.3% below the 52-week high.
Oct 6, 2026 — NXTC jumps 12.6% to $5.68
- Closed at $5.68, +12.57% vs the prior close of $5.05. Day range $5.00–$5.91, opened at $5.01.
- Volume was 122.50K shares, 0.6x its 50-day average of 218.78K — lighter than usual.
- Price is -7.6% vs its 50-day average ($6.15) and -32.9% vs its 200-day average ($8.47).
- 52-week range $1.55–$15.74; today's close sits at 29% of that range, 63.9% below the 52-week high.
Oct 5, 2026 — NXTC dips 0.8% to $5.05
- Closed at $5.05, -0.79% vs the prior close of $5.09. Day range $4.94–$5.19, opened at $5.05.
- Volume was 14.60K shares, 0.1x its 50-day average of 224.14K — lighter than usual.
- Price is -17.7% vs its 50-day average ($6.14) and -40.5% vs its 200-day average ($8.49).
- 52-week range $1.55–$15.74; today's close sits at 25% of that range, 67.9% below the 52-week high.
Oct 2, 2026 — NXTC rises 2.6% to $5.09
- Closed at $5.09, +2.62% vs the prior close of $4.96. Day range $4.85–$5.40, opened at $5.17.
- Volume was 63.30K shares, 0.3x its 50-day average of 227.93K — lighter than usual.
- Price is -16.9% vs its 50-day average ($6.12) and -40.3% vs its 200-day average ($8.52).
- 52-week range $1.55–$15.74; today's close sits at 25% of that range, 67.7% below the 52-week high.
NXTC latest news & SEC filings
Every SEC filing by or about NXTC in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 25, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Sep 3, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
Aug 14, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 13, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 12, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 12, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. sold 30,000 shares at $6.16 (≈$184.80K) on Aug 10, 2026
- Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. sold 30,000 shares at $6.16 (≈$184.80K) on Aug 10, 2026
- Ren Jinsheng sold 30,000 shares at $6.16 (≈$184.80K) on Aug 10, 2026
- Ren Jinsheng sold 30,000 shares at $6.16 (≈$184.80K) on Aug 10, 2026
- Simcere Pharmaceutical Group Ltd sold 30,000 shares at $6.16 (≈$184.80K) on Aug 10, 2026
- Simcere Pharmaceutical Group Ltd sold 30,000 shares at $6.16 (≈$184.80K) on Aug 10, 2026
- …plus 18 more transaction lines in the filing.
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 6, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$14.89M (prior year -$26.81M) (loss narrowed vs Jun 30, 2025)
- Diluted EPS: -$2.80 (prior year -$11.29) (loss narrowed vs Jun 30, 2025)
Aug 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Things to know before you trade NXTC
- Last results release: Aug 6, 2026 (8-K Item 2.02). Previous ones: May 7, 2026, Mar 5, 2026, Jan 23, 2026. Based on that rhythm, the next report is likely around Nov 5, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 5.87% (largest 15.4%). That is a volatile stock.
- Liquidity: about 91.59K shares (≈$571.55K) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $6.24 vs a range of $1.55–$15.74 (33% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: 1:12 on Jul 14, 2025
- Insider trades (Form 4, last 12 months, recent 25 shown): 1 open-market buys, 24 sales; latest: Simcere Zaiming Pharmaceutical Co., Ltd. Jiangsu sold 30,000 shares on Aug 10, 2026.
- Latest filings: 8-K Sep 25, 2026; 8-K Sep 3, 2026; 10-Q Aug 6, 2026.
- Share count: 4.58M shares outstanding (Jul 31, 2026), +71.0% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
NXTC market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 6.61 | 6.66 | 6.10 | 6.24 | 39.00K |
| Oct 15, 2026 | 6.59 | 7.22 | 6.59 | 6.88 | 72.40K |
| Oct 14, 2026 | 6.16 | 6.86 | 6.11 | 6.58 | 51.60K |
| Oct 13, 2026 | 6.58 | 6.80 | 6.21 | 6.28 | 54.70K |
| Oct 12, 2026 | 7.08 | 7.52 | 6.03 | 6.64 | 130.40K |
| Oct 9, 2026 | 6.68 | 7.20 | 6.30 | 7.18 | 85.70K |
| Oct 8, 2026 | 6.24 | 6.94 | 6.05 | 6.78 | 82.60K |
| Oct 7, 2026 | 5.70 | 6.72 | 5.42 | 6.56 | 109.50K |
| Oct 6, 2026 | 5.01 | 5.91 | 5.00 | 5.68 | 122.50K |
| Oct 5, 2026 | 5.05 | 5.19 | 4.94 | 5.05 | 14.60K |
| Oct 2, 2026 | 5.17 | 5.40 | 4.85 | 5.09 | 63.30K |
| Oct 1, 2026 | 4.99 | 5.19 | 4.85 | 4.96 | 46.50K |
| Sep 30, 2026 | 5.14 | 5.16 | 4.91 | 5.01 | 34.10K |
| Sep 29, 2026 | 5.00 | 5.22 | 4.78 | 4.84 | 55.40K |
| Sep 28, 2026 | 5.02 | 5.30 | 5.00 | 5.08 | 63.20K |
| Sep 25, 2026 | 5.27 | 5.56 | 5.02 | 5.08 | 71.80K |
| Sep 24, 2026 | 4.80 | 5.65 | 4.80 | 5.28 | 226.80K |
| Sep 23, 2026 | 5.12 | 5.19 | 4.64 | 4.82 | 225.80K |
| Sep 22, 2026 | 5.59 | 5.90 | 4.87 | 5.18 | 156.10K |
| Sep 21, 2026 | 6.09 | 6.30 | 5.32 | 5.46 | 125.90K |
About NextCure
NextCure (NXTC) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in BALTIMORE, MD. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1661059.
NXTC board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Anne Elizabeth Borgman | Director | Jun 22, 2026 |
| Ellen Feigal | Director | Jun 22, 2026 |
| John G Houston | Director | Jun 22, 2026 |
| Elaine V Jones | Director | Jun 22, 2026 |
| David S Kabakoff | Director | Jun 22, 2026 |
| Michael Richman | President & CEO | Feb 3, 2026 |
| Stephen W Webster | Director | Jun 22, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Steven P. Cobourn | Chief Financial Officer | Feb 3, 2026 |
| Udayan Guha | Chief Medical Officer | Feb 3, 2026 |
| Sourav Kundu | Sr VP, Dev. & Mfg. | Feb 3, 2026 |
| Timothy Mayer | Chief Operating Officer | Feb 3, 2026 |
| Michael Richman | President & CEO | Feb 3, 2026 |
| Kevin G. Shaw | Sr VP, General Counsel | Feb 3, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 10, 2026 | Simcere Zaiming Pharmaceutical Co., Ltd. Jiangsu | Sale | 30,000 | $6.16 |
| Aug 10, 2026 | Simcere Zaiming Pharmaceutical Co., Ltd. Jiangsu | Sale | 30,000 | $6.16 |
| Aug 10, 2026 | Jinsheng Ren | Sale | 30,000 | $6.16 |
| Aug 10, 2026 | Jinsheng Ren | Sale | 30,000 | $6.16 |
| Aug 10, 2026 | Pharmaceutical Group Ltd Simcere | Sale | 30,000 | $6.16 |
| Aug 10, 2026 | Pharmaceutical Group Ltd Simcere | Sale | 30,000 | $6.16 |
| Aug 10, 2026 | Renhong Tang | Sale | 30,000 | $6.16 |
| Aug 10, 2026 | Renhong Tang | Sale | 30,000 | $6.16 |
| Aug 10, 2026 | Zaiming Pharmaceutical Co., Ltd. Simcere | Sale | 30,000 | $6.16 |
| Aug 10, 2026 | Zaiming Pharmaceutical Co., Ltd. Simcere | Sale | 30,000 | $6.16 |
| Aug 10, 2026 | Zaiming, Inc. Simcere | Sale | 30,000 | $6.16 |
| Aug 10, 2026 | Zaiming, Inc. Simcere | Sale | 30,000 | $6.16 |
| Aug 10, 2026 | Simcere Zaiming Pharmaceutical Co., Ltd. Jiangsu | Sale | 30,000 | $6.16 |
| Aug 10, 2026 | Simcere Zaiming Pharmaceutical Co., Ltd. Jiangsu | Sale | 30,000 | $6.16 |
| Aug 10, 2026 | Jinsheng Ren | Sale | 30,000 | $6.16 |
NXTC financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-55.84M | -19.65 | $-49.61M |
| Dec 31, 2024 | — | $-55.65M | -23.88 | $-40.80M |
| Dec 31, 2023 | — | $-62.72M | -2.25 | $-52.97M |
| Dec 31, 2022 | — | $-74.73M | -2.69 | $-53.89M |
| Dec 31, 2021 | — | $-69.39M | -2.51 | $-57.28M |
Latest balance sheet: total assets $22.62M, total liabilities $10.47M, cash $15.26M (as of Jun 30, 2026).
NXTC earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 6, 2026 | 8-K Item 2.02 (results) | $5.59 |
| May 7, 2026 | 8-K Item 2.02 (results) | $10.18 |
| Mar 5, 2026 | 8-K Item 2.02 (results) | $12.76 |
| Jan 23, 2026 | 8-K Item 2.02 (results) | $11.92 |
| Nov 5, 2025 | 8-K Item 2.02 (results) | $9.63 |
| Aug 7, 2025 | 8-K Item 2.02 (results) | $5.09 |
| May 1, 2025 | 8-K Item 2.02 (results) | $5.76 |
| Mar 6, 2025 | 8-K Item 2.02 (results) | $8.56 |
| Nov 7, 2024 | 8-K Item 2.02 (results) | $15.84 |
| Aug 1, 2024 | 8-K Item 2.02 (results) | — |
| May 2, 2024 | 8-K Item 2.02 (results) | — |
| Mar 21, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on NXTC
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.